Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.
Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback